S almonella enterica serovar T yphimurium immunotherapy for B‐cell lymphoma induces broad anti‐tumour immunity with therapeutic effect

Despite the efficacy of current immune‐chemotherapy for treatment of B ‐cell non‐ H odgkin lymphoma, a substantial proportion of patients relapse, highlighting the need for new therapeutic modalities. The use of live microorganisms to develop anti‐tumoural therapies has evolved since C oley's toxin and is now receiving renewed attention. S almonella T yphimurium has been shown to be highly effective as an anti‐tumour agent in many solid cancer models, but it has not been used in haemato‐oncology. Here, we report that intra‐tumoural administration of LVR 01 (attenuated S . T yphimurium strain with safety profile) elicits local and systemic anti‐tumour immunity, resulting in extended survival in a lymphoma model. LVR 01 induces intra‐tumoural recruitment of neutrophils and activated CD 8 + T cells, as well as increasing the natural killer cell activation status. Furthermore, a systemic specific anti‐tumour response with a clear T helper type 1 profile was observed. This approach is an alternative therapeutic strategy for lymphoma patients that could be easily moved into clinical trials.